On September 16, 2026 Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, reported an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly’s proprietary research data. Participating companies may use the TuneLab prediction models to more rapidly down-select candidate molecules. Through this agreement, users will be able to order antibody services from Twist using TuneLab preferred Twist protocols to generate high-quality wet lab data. This approach connects experimental data with AI-enabled discovery, allowing researchers to potentially accelerate antibody drug discovery.
"The quality of an AI model’s output depends on the quality of the data used to train it," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "Twist has the scale and high-throughput capabilities to generate consistent and reliable antibody characterization data these models need to be trained on. Lilly’s leadership in empowering AI-enabled drug discovery and its impressive network of partnerships create a powerful ecosystem that brings together advanced models and high-quality data. Through this arrangement, TuneLab users can select preferred protocols to generate high-quality data with preferred pricing – both helping them to more efficiently select antibody sequences against their targets and contribute that data back to TuneLab for federated training."
Lilly TuneLab is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.
(Press release, Twist Bioscience, SEP 16, 2026, View Source [SID1234670900])